IL2 and melanoma: During the early 1990s, clinical trials of high-dose IL-2 in patients with metastatic renal cell carcinoma and malignant melanoma showed that some patients with metastatic renal cell carcinoma and metastatic melanoma benefited from high-dose IL-2 treatment [37,38].